TSVT Key Statistics, Chart & Performance
The current stock price of TSVT is 5 USD. In the past month the price increased by 0.81%. In the past year, price increased by 4.17%.
TSVT Latest News, Press Relases and Analysis
TSVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About TSVT
Company Profile
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Company Info
2SEVENTY BIO INC
60 Binney Street
Cambridge MASSACHUSETTS US
Employees: 274
Phone: 13394999300
2SEVENTY BIO INC / TSVT FAQ
What does 2SEVENTY BIO INC do?
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Can you provide the latest stock price for 2SEVENTY BIO INC?
The current stock price of TSVT is 5 USD. The price increased by 0.2% in the last trading session.
Does 2SEVENTY BIO INC pay dividends?
TSVT does not pay a dividend.
What is the ChartMill rating of 2SEVENTY BIO INC stock?
TSVT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about 2SEVENTY BIO INC (TSVT) stock?
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5.
Can you provide the PE ratio for TSVT stock?
2SEVENTY BIO INC (TSVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).
Can you provide the market cap for 2SEVENTY BIO INC?
2SEVENTY BIO INC (TSVT) has a market capitalization of 266.15M USD. This makes TSVT a Micro Cap stock.
TSVT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TSVT. When comparing the yearly performance of all stocks, TSVT is one of the better performing stocks in the market, outperforming 95.69% of all stocks.
TSVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TSVT. TSVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TSVT Financial Highlights
Over the last trailing twelve months TSVT reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 72.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.94% | ||
| ROE | -27.16% | ||
| Debt/Equity | 0 |
TSVT Forecast & Estimates
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5.
For the next year, analysts expect an EPS growth of 58.41% and a revenue growth 42.31% for TSVT